MDCG 2020-16 Rev.5 Clarifies Rule 7 for IVD Quality Controls

The European Commission published MDCG 2020-16 revision 5 on 9 September 2026. The revision clarifies how Rule 7 applies to standalone IVD quality control materials, including the distinction between an indicative concentration range and an assigned value.

The September 2026 guidance is endorsed by the Medical Device Coordination Group (MDCG). It is non-binding guidance, not an amendment to the In Vitro Diagnostic Medical Devices Regulation (IVDR). Its revision table identifies the Rule 7 rationale and examples as the revision-5 changes. It sets no implementation date or transition deadline.

The legal classification rules remain in place

Annex VIII of the IVDR already separates two cases:

• Rule 7: controls without a quantitative or qualitative assigned value are class B.
• Implementing rule 1.6: control materials with quantitative or qualitative assigned values, intended for one or more specific analytes, take the same class as the device.

Revision 5 explains the boundary between those cases; it does not rewrite the rules. A manufacturer's classification assessment must still consider the intended purpose and any other applicable rules.

An indicative range is not automatically an assigned value

The rationale on pages 45–46 distinguishes the values a manufacturer indicates from the target values a laboratory determines for routine use. A manufacturer may provide information about an analyte's presence or concentration range for a standalone quality control (QC) material. In the context described by the guidance, those indicative values are not assigned values, and Rule 7 gives class B unless other rules apply.

By contrast, controls with quantitative or qualitative values assigned by their manufacturer fall under implementing rule 1.6. Revision 5 expressly includes assay kit validity controls in this category. The word “standalone” or the presence of a number on a label is therefore insufficient, by itself, to decide which rule applies.

What the guidance says about the IFU

The revised rationale says the instructions for use (IFU) must clearly limit the intended purpose of the standalone QC materials it describes to monitoring the validity of laboratory examination procedures. It also states that these materials cannot replace the mandatory QC materials used to verify the IVD's own performance.

This is an expectation expressed in non-binding guidance. It should be assessed alongside the product's documented intended purpose and classification rationale, rather than presented as a newly enacted labelling law or a universal condition that independently determines class B.

The guidance's non-exhaustive examples include unassigned control sera; migration controls for immunochromatographic assays; unassigned heterozygous controls for nucleic-acid extraction, amplification and detection; non-assay-specific coagulation plasma; multi-analyte biochemical control serum; and non-assay-specific normal DNA or RNA controls for in situ hybridisation.

There is also a scope limit: internationally certified reference materials and materials used for external quality assessment schemes are excluded from the IVDR under Article 1(3)(c) and (d). They should not simply be placed in the Rule 7 class B category.

A focused documentation review

Pure Global analysis: review the product in this order:

1. Establish its role. Is it a material excluded from the IVDR, a standalone QC material of the kind discussed in Rule 7, or a control with manufacturer-assigned values?
2. Reconcile the documents. Compare the intended purpose, the way values are described in the IFU, and the classification rationale. An indicative range and a manufacturer-assigned target should not be described interchangeably.
3. Check the intended-purpose limitation. Where the revised standalone-QC rationale applies, assess whether the IFU communicates the laboratory-monitoring purpose and the limitation on replacing the IVD's own QC materials.

Record the assessment through the existing document-review process. The guidance provides no universal refiling requirement or revision-5 compliance date; any resulting product-specific action needs its own regulatory assessment.

For related context, see IVD intended purpose and IVDR classification.